effective in controlling active, nonsevere disease, or if the patient has nonsevere vasculitis (which in some series included mononeuritis multiplex) and is positive for ANCA. Cyclophosphamide should be avoided when treating active, nonsevere disease due to its toxicity and is the least preferred option in this setting. Remission maintenance Recommendation: For patients with severe EGPA whose disease has entered remission with cyclophosphamide therapy, we conditionally recommend treatment with